Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Position Lowered by Millennium Management LLC

Millennium Management LLC cut its position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 94.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,133 shares of the biotechnology company's stock after selling 165,920 shares during the quarter. Millennium Management LLC owned 0.18% of Atara Biotherapeutics worth $135,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ATRA. Northern Trust Corp bought a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at about $149,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $169,000. Birchview Capital LP bought a new stake in shares of Atara Biotherapeutics in the 4th quarter worth approximately $293,000. Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the 4th quarter worth approximately $332,000. Finally, Staley Capital Advisers Inc. boosted its position in Atara Biotherapeutics by 25.0% during the 4th quarter. Staley Capital Advisers Inc. now owns 50,000 shares of the biotechnology company's stock valued at $666,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 70.90% of the company's stock.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reiterated a "buy" rating and issued a $17.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Atara Biotherapeutics has an average rating of "Moderate Buy" and an average price target of $17.75.

Atara Biotherapeutics Price Performance

ATRA stock traded up $0.11 on Friday, reaching $8.82. The company's stock had a trading volume of 34,168 shares, compared to its average volume of 125,632. Atara Biotherapeutics, Inc. has a 52 week low of $5.01 and a 52 week high of $18.71. The company has a market capitalization of $52.58 million, a P/E ratio of -0.34 and a beta of 0.19. The firm has a fifty day moving average of $7.18 and a two-hundred day moving average of $8.76.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The biotechnology company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of ($3.07) by $6.57. The business had revenue of $98.10 million for the quarter, compared to analyst estimates of $4.30 million. As a group, equities analysts expect that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.